Study on the Clinical Application Value of Serum Inflammatory Markers in Benign Prostatic Hyperplasia.

Background: The aim of this study was to explore the clinical application value of serum inflammatory markers in the diagnosis and treatment of benign prostatic hyperplasia (BPH) in elderly men.

Methods: From April 2023 through July 2023, 110 BPH patients and 120 healthy individuals who underwent examinations at our hospital were selected as study subjects. The concentrations of C-reactive protein (CRP), procalcitonin (PCT), serum amyloid A (SAA), complement 3 (C3), and complement 4 (C4) were measured in both groups.

Results: The concentrations of CRP and SAA in the BPH patient group were significantly higher than those in the healthy control group (p < 0.05). There was a significant correlation between BPH and the concentrations of CRP and SAA, but no correlation with PCT, C3, or C4. ROC curve analysis indicates that both SAA and CRP have high diagnostic efficacy for BPH. Furthermore, the combined use of SAA and CRP provides the better diagnostic performance. This combined approach has the potential to support physicians in guiding diagnosis and treatment.

Conclusions: Serum inflammatory markers can serve as independent factors for BPH. Among them, CRP and SAA are significantly positively correlated with BPH, which is of great significance for the non-invasive diagnosis of BPH.